Circulating Cerebral S100B Protein Is Associated with Depressive Symptoms following Myocardial Infarction
| Autor: | M. Quere, H. Storm, Adriaan Honig, de Peter Jonge, Dorien Tulner, van Jochum Melle, Jannes Slomp, J.A. den Boer, Otto R.F. Smith, Jakob Korf |
|---|---|
| Přispěvatelé: | Medical and Clinical Psychology, Science in Healthy Ageing & healthcaRE (SHARE), Interdisciplinary Centre Psychopathology and Emotion regulation (ICPE), Life Course Epidemiology (LCE), Cardiovascular Centre (CVC) |
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Time Factors NEURON-SPECIFIC ENOLASE Traumatic brain injury TRAUMATIC BRAIN-INJURY Infarction Pilot Projects SERUM S100B S100 Calcium Binding Protein beta Subunit MINOR HEAD-INJURY Gastroenterology HIPPOCAMPAL NEUROGENESIS Pathogenesis Internal medicine Humans Medicine Nerve Growth Factors Myocardial infarction CARDIOVASCULAR EVENTS Biological Psychiatry Depression (differential diagnoses) Aged Depression business.industry S100 Proteins Depressive symptoms Beck Depression Inventory NECROSIS-FACTOR-ALPHA MAJOR DEPRESSION Middle Aged WHITE-MATTER LESIONS medicine.disease Hyperintensity Cardiac surgery Psychiatry and Mental health Neuropsychology and Physiological Psychology Anesthesia Female business Biomarkers S100B protein CARDIAC-SURGERY |
| Zdroj: | Neuropsychobiology, 59(2), 87-95. S. Karger AG Neuropsychobiology, 59(2), 87-95. KARGER |
| ISSN: | 1423-0224 0302-282X |
| DOI: | 10.1159/000209860 |
| Popis: | Background: Prevalence of depressive symptoms in the post-myocardial infarction (MI) period varies from 8 to 30%. Cerebral damage after MI, caused by transient ischemia, an inflammatory response or both, may contribute to development of post-MI depression. S100B is an established protein marker of cerebral damage. In a pilot study, the authors assessed whether S100B serum levels are: (1) increased during the week after MI, and (2) related to depressive symptoms during index hospital admission and the year following MI. Methods: This pilot study is a substudy of the Myocardial Infarction and Depression Intervention Trial (MIND-IT). In 48 patients, serum levels of S100B were available at 1, 2, 3, 4 and 8 days following MI. Subsequently, in 27 patients, depressive symptoms were measured at 0, 3, 6, 9 and 12 months following MI with the Beck Depression Inventory (BDI). In 21 of the initial 48 patients, BDI data were lacking due to refusals to fill out BDI forms or missing data. Results: Significant and transient increases in serum S100B were observed in 81.3% of the 48 patients: 37.5% reached S100B serum levels comparable to serum levels found in acute brain injury (>0.20 μg/l) and 43.8% reached mildly elevated S100B serum levels comparable to serum levels found in depressive disorder (0.10–0.20 μg/l). In 18.7%, no S100B was detected in serum. Using non-parametric Spearman rank correlation tests, a trend towards an association was found between serum S100B and depressive symptoms during the post-MI year (ρ values between 0.16 and 0.53) in 27 patients who completed both the S100B serum study and the BDI study. Conclusion: Transiently elevated levels of S100B are suggestive of minor acute cerebral damage in the first days following MI and associated with depressive symptoms in the year following MI. Cerebral damage could be an important mechanism in the pathogenesis in a subtype of post-MI depression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|